Compare Tempus AI (TEM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs State Street SPDR S&P Biotech ETF — how do they compare? Tempus AI trades at $54.84 (market cap $10.05B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| TEM | XBI | |
|---|---|---|
Market Cap | $10.05B | — |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $103.25 | $164.28 |
52-Week Low | $41.55 | $86.92 |
Enterprise Value | $10.68B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $54.99, down 0.13% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed a narrower loss than expected and revenue beat, driving positive sentiment. The company is expanding through acquisitions like Personalis and launching new services, though it remains unprofitable with negative margins.
The outlook is cautiously optimistic due to revenue growth and strategic initiatives, but high valuation ratios and persistent losses pose risks. Upside is supported by a $61.57 consensus price target, while competitive and execution challenges require monitoring for sustained investor confidence.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
